EIF2AK3 Antibody

What is EIF2AK3/PERK and why is it important in biological research?

EIF2AK3 (PERK) is one of four kinases that specifically phosphorylate Ser51 of translation initiation factor eIF2-alpha in response to various environmental stresses, leading to decreased protein synthesis. Signaling is initiated by misfolded proteins in the endoplasmic reticulum (ER). EIF2AK3 is essential in tissues with high protein synthesis demands, particularly osteoblasts and pancreatic islet cells. Dysregulation of EIF2AK3 activity has been implicated in various diseases, including neurodegenerative disorders, diabetes, and cancer . Understanding EIF2AK3 function is crucial for investigating cellular stress responses, protein folding pathways, and developing targeted disease therapies.

What types of EIF2AK3 antibodies are available for research applications?

Currently, several polyclonal antibodies targeting EIF2AK3/PERK are commercially available for research. These include rabbit polyclonal antibodies like 20582-1-AP, 24390-1-AP, and CAB18196 . These antibodies are primarily IgG isotype and are supplied in liquid form, typically in PBS buffer with sodium azide and glycerol for stability . They are designed for multiple applications including Western blot, immunohistochemistry, immunofluorescence, and flow cytometry, with demonstrated reactivity against human samples and, in some cases, mouse and rat samples as well .

What are the recommended applications for EIF2AK3 antibodies?

EIF2AK3 antibodies have been validated for several applications with specific recommended dilutions:

It is important to note that these antibodies should be titrated in each testing system to obtain optimal results, as performance can be sample-dependent . Published applications include knock-down/knock-out validation, co-immunoprecipitation, and various imaging techniques .

How should I optimize Western blot conditions for detecting EIF2AK3?

For optimal Western blot detection of EIF2AK3, start with a 1:500-1:2000 dilution of the primary antibody . When preparing samples, be aware that the calculated molecular weight of EIF2AK3 is approximately 125 kDa, but the observed molecular weight in Western blots is typically around 140 kDa due to post-translational modifications . Use appropriate positive controls such as lysates from HEK-293, HepG2, or MCF-7 cells, which have been validated to express detectable levels of EIF2AK3 . For immunoblot analysis of EIF2AK3 activity, consider measuring phospho-eIF2α levels, as eIF2α is the only known substrate of EIF2AK3 . Include both phospho-specific and total eIF2α antibodies to normalize your results, and include a standard control sample across blots to account for inter-experimental variability.

What is the best approach for studying EIF2AK3 activation during ER stress responses?

To study EIF2AK3 activation during ER stress, researchers commonly use chemical inducers such as thapsigargin (TG), an ER Ca²⁺-ATPase inhibitor . A validated approach involves treating cells with TG (typically at 2 μM concentration) and measuring the changes in phospho-eIF2α levels using immunoblot analysis at various time points .

When conducting these experiments:

• Include time course measurements to capture the dynamic nature of the response

• Use appropriate antibodies for both phospho-eIF2α (such as 1:1000 dilution; Cell Signaling) and total eIF2α (1:1000 dilution)

• Normalize phospho-eIF2α levels to total eIF2α to correct for loading variations

• Include a standard control sample across experiments to normalize for inter-experimental variability in signal strength

• Consider using densitometric analysis software (such as Quantity One) for quantitative assessment

This approach allows for reliable assessment of EIF2AK3 activity in response to ER stress induction.

What considerations are important for immunohistochemical detection of EIF2AK3?

For successful immunohistochemical detection of EIF2AK3, several important technical considerations should be addressed:

• Antigen retrieval: For optimal staining, use TE buffer at pH 9.0 for antigen retrieval. Alternatively, citrate buffer at pH 6.0 may be used, though results may vary .

• Antibody dilution: Start with a dilution range of 1:50-1:500 and optimize based on your specific sample type and detection method .

• Positive control tissues: Human pancreatic cancer tissue and human liver cancer tissue have been validated as positive controls for IHC with different EIF2AK3 antibodies . Including these controls will help validate your staining protocol.

• Signal specificity: To ensure specificity, consider including appropriate negative controls, such as isotype controls or tissues from EIF2AK3 knockout models when available.

• Detection system: Select a detection system compatible with rabbit primary antibodies, as most available EIF2AK3 antibodies are rabbit-derived .

How can I investigate the relationship between EIF2AK3 genetic variants and disease phenotypes?

To investigate EIF2AK3 genetic variants and their relationship to disease phenotypes, researchers can employ a multi-faceted approach that integrates genetic analysis with functional studies:

• Genetic variant identification: Screen for known variants such as rs13045, rs6547787 (promoter SNP), and nonsynonymous SNPs (rs867529 and rs1805165) which have been associated with disease risk .

• Haplotype analysis: Consider analyzing complete haplotypes rather than individual SNPs. Research has identified specific haplotypes (such as haplotype B with MAF = 0.311 associated with low bone mineral density) that may have functional significance .

• Functional characterization: To determine if identified variants affect EIF2AK3 function, measure phospho-eIF2α levels in patient-derived or genetically modified cell lines before and after ER stress induction. For example, lymphoblastoid cell lines with haplotype B showed increased sensitivity to ER stress compared to those with haplotype A (P = 0.014) .

• Expression analysis: Although some variants may not affect mRNA expression levels under basal conditions, they might alter response to stress. Therefore, compare expression and activity under both basal and stress conditions .

• Phenotype correlation: Correlate variant presence with clinical parameters relevant to the disease of interest, such as bone mineral density measurements for osteoporosis studies .

This integrated approach allows for comprehensive assessment of how EIF2AK3 genetic variation contributes to disease susceptibility and progression.

What strategies can be employed to study EIF2AK3's role in tissue-specific pathologies?

EIF2AK3 exhibits tissue-specific expression and functions, particularly in tissues with high protein synthesis demands such as osteoblasts and pancreatic islet cells. To study its role in tissue-specific pathologies:

• Tissue-specific models: Utilize tissue-specific conditional knockout models to investigate EIF2AK3 function in particular cell types. This approach helps overcome the limitations of global knockouts, which can be lethal or have pleiotropic effects.

• Primary cell cultures: Isolate primary cells from tissues of interest (e.g., osteoblasts, pancreatic β-cells) to study EIF2AK3 function in a more physiologically relevant context than immortalized cell lines .

• Stress response characterization: Compare ER stress responses across different tissue types using phospho-eIF2α measurements following thapsigargin treatment, as detailed in published protocols .

• Disease model integration: Incorporate EIF2AK3 analysis into established disease models, such as diabetes (for pancreatic studies) or osteoporosis models (for bone studies) .

• Therapeutic intervention assessment: Evaluate how modulating EIF2AK3 activity affects disease progression in tissue-specific contexts, potentially identifying targeted therapeutic approaches.

By employing these strategies, researchers can elucidate how EIF2AK3 dysfunction contributes to tissue-specific pathologies and identify potential therapeutic targets.

How can multiplexed assays be designed to study EIF2AK3 in complex signaling networks?

Designing multiplexed assays to study EIF2AK3 within complex signaling networks requires careful consideration of multiple interacting pathways:

• Multi-parameter flow cytometry: Develop protocols that simultaneously detect phospho-EIF2AK3, phospho-eIF2α, and other UPR pathway components. Flow cytometry has been validated for detecting intracellular EIF2AK3 using a concentration of 0.40 μg antibody per 10^6 cells .

• Phospho-protein arrays: Implement phospho-protein arrays to simultaneously assess multiple stress response pathways, including EIF2AK3/PERK, IRE1α, and ATF6 branches of the unfolded protein response.

• Time-course analyses: Capture the dynamic nature of EIF2AK3 signaling by collecting measurements at multiple time points after stress induction, as different pathways may have distinct temporal activation patterns.

• Inhibitor studies: Use selective inhibitors for different stress response pathways to dissect their relative contributions and cross-talk. When studying EIF2AK3 specifically, compare responses to different ER stress inducers such as thapsigargin, tunicamycin, or DTT.

• Image-based approaches: For spatial information, consider multiplexed immunofluorescence to visualize the co-localization and activation patterns of EIF2AK3 with other proteins in the ER stress response network.

By integrating these approaches, researchers can gain a more comprehensive understanding of how EIF2AK3 functions within broader cellular stress response networks.

How should I interpret variations in EIF2AK3 antibody performance across different cell types?

When encountering variations in EIF2AK3 antibody performance across different cell types, consider several factors that may influence detection and interpretation:

• Expression levels: EIF2AK3 is ubiquitously expressed but with variable abundance across tissues. It is particularly abundant in osteoblasts and pancreatic islet cells . Verify expected expression in your cell type through literature or database searches.

• Post-translational modifications: The observed molecular weight of EIF2AK3 (approximately 140 kDa) differs from its calculated weight (125 kDa) , suggesting significant post-translational modifications that may vary between cell types and affect antibody recognition.

• Isoform expression: Check if your cell type expresses specific EIF2AK3 isoforms that might not be recognized by your antibody.

• Optimized protocols: Different cell types may require modified lysis conditions, antigen retrieval methods, or antibody concentrations. For IHC applications, TE buffer at pH 9.0 is generally recommended, but citrate buffer at pH 6.0 may work better for certain tissues .

• Positive controls: Include validated positive controls in your experiments. HEK-293, HepG2, and MCF-7 cells have been confirmed to express detectable levels of EIF2AK3 for Western blot applications .

Carefully documenting these variations can provide valuable information about tissue-specific EIF2AK3 regulation and function.

What are common challenges in measuring EIF2AK3 activity and how can they be addressed?

Measuring EIF2AK3 activity presents several challenges that researchers should anticipate and address:

• Indirect measurement: Since EIF2AK3 activity is typically measured indirectly through phosphorylation of its substrate eIF2α, researchers must carefully control for factors that might affect eIF2α phosphorylation independent of EIF2AK3. Other kinases (GCN2, PKR, and HRI) can also phosphorylate eIF2α at the same site (Ser51) . Consider using specific inhibitors or genetic approaches to isolate EIF2AK3-specific effects.

• Temporal dynamics: The phosphorylation of eIF2α is dynamic and can change rapidly after stress induction. Conduct detailed time-course experiments to capture the full response profile rather than single time point measurements .

• Normalization: Always normalize phospho-eIF2α levels to total eIF2α to account for variations in protein loading. Additionally, include a standard control sample across experiments to normalize for inter-experimental variability in signal strength .

• Background stress: Cell culture conditions can inadvertently induce stress responses. Maintain consistent culture conditions and include appropriate unstressed controls.

• Quantification methods: Use reliable densitometric software for quantitative assessment of immunoblot signals. Programs like Quantity One software (Bio-Rad) have been successfully employed in published studies .

By addressing these challenges systematically, researchers can obtain more reliable and reproducible measurements of EIF2AK3 activity.

How can I validate the specificity of my EIF2AK3 antibody for my experimental system?

Validating antibody specificity is crucial for reliable experimental results. For EIF2AK3 antibodies, consider implementing these validation strategies:

• Genetic validation: Use cellular models with EIF2AK3 knockdown or knockout to confirm antibody specificity. Published applications include numerous studies using KD/KO systems . The absence or reduction of signal in these models strongly supports antibody specificity.

• Multiple antibodies: Compare results using different antibodies targeting distinct epitopes of EIF2AK3. For example, compare antibodies targeting different regions such as CAB18196 (targeting amino acids 867-1116) with other commercially available antibodies.

• Recombinant protein controls: Use purified recombinant EIF2AK3 protein as a positive control for antibody binding. This approach is particularly useful for determining antibody sensitivity and detecting potential cross-reactivity.

• Immunoprecipitation followed by mass spectrometry: For the most rigorous validation, perform immunoprecipitation with your EIF2AK3 antibody followed by mass spectrometry to confirm the identity of the precipitated protein.

• Expected molecular weight verification: Confirm that your detected band appears at the expected molecular weight. For EIF2AK3, the calculated molecular weight is approximately 125 kDa, but the observed molecular weight in Western blots is typically around 140 kDa due to post-translational modifications .

Thorough validation not only ensures experimental reliability but also contributes to reproducibility in the broader scientific community.

How can EIF2AK3 antibodies be utilized in studying the integrated stress response in complex disease models?

EIF2AK3 antibodies offer valuable tools for investigating the integrated stress response (ISR) in complex disease models:

• Multi-tissue analysis: In systemic disease models, use EIF2AK3 antibodies for immunohistochemical analysis across multiple tissues to map the distribution of ER stress. The antibodies have been validated for IHC in tissues such as human pancreatic cancer tissue and liver cancer tissue .

• Stress response profiling: Combine EIF2AK3/phospho-eIF2α detection with markers of other stress pathways to create comprehensive stress response profiles in disease states. This is particularly relevant for neurodegenerative diseases, diabetes, and cancer, where EIF2AK3 dysregulation has been implicated .

• Therapeutic response monitoring: Use EIF2AK3 antibodies to monitor changes in the ER stress response following therapeutic interventions. This application is especially valuable for drug development targeting the unfolded protein response.

• Genetic background integration: Combine EIF2AK3 activity measurements with genotyping for known functional variants (such as rs867529 and rs1805165) to understand how genetic factors influence stress responses in disease contexts .

• Longitudinal studies: In progressive disease models, track changes in EIF2AK3 expression and activity over time to understand how ER stress evolves during disease progression.

These applications enable researchers to better understand how ER stress contributes to disease pathogenesis and identify potential points for therapeutic intervention.

What novel approaches combine EIF2AK3 antibodies with advanced imaging techniques?

Integrating EIF2AK3 antibodies with advanced imaging techniques offers powerful new research capabilities:

• Super-resolution microscopy: Apply techniques such as STORM or PALM with EIF2AK3 antibodies to visualize the nanoscale organization of EIF2AK3 within the ER membrane. This can provide insights into how EIF2AK3 clustering may regulate its activation during stress.

• Live-cell imaging: Develop approaches using cell-permeable antibody fragments or genetically encoded sensors based on EIF2AK3 binding domains to monitor dynamic changes in EIF2AK3 activation in living cells.

• Correlative light and electron microscopy (CLEM): Combine immunofluorescence detection of EIF2AK3 with electron microscopy to correlate its localization with ultrastructural changes in the ER during stress responses.

• Multiplexed imaging: Implement cyclic immunofluorescence or mass cytometry imaging to simultaneously visualize multiple components of the ER stress response, including EIF2AK3, in tissue sections or complex cellular systems.

• Intravital microscopy: For in vivo studies, explore the application of fluorescently labeled EIF2AK3 antibodies with intravital microscopy to monitor ER stress responses in live animal models of disease.

These emerging imaging approaches can provide unprecedented insights into EIF2AK3 biology and its role in cellular stress responses within physiologically relevant contexts.